| Literature DB >> 33783512 |
Paul Jongseo Lee1,2, Suzhou Yang1,2, Yu Sun1, Junjie U Guo1,2.
Abstract
Eukaryotes have evolved a variety of mRNA surveillance mechanisms to detect and degrade aberrant mRNAs with potential deleterious outcomes. Among them, nonsense-mediated mRNA decay (NMD) functions not only as a quality control mechanism targeting aberrant mRNAs containing a premature termination codon but also as a posttranscriptional gene regulation mechanism targeting numerous physiological mRNAs. Despite its well-characterized molecular basis, the regulatory scope and biological functions of NMD at an organismal level are incompletely understood. In humans, mutations in genes encoding core NMD factors cause specific developmental and neurological syndromes, suggesting a critical role of NMD in the central nervous system. Here, we review the accumulating biochemical and genetic evidence on the developmental regulation and physiological functions of NMD as well as an emerging role of NMD dysregulation in neurodegenerative diseases.Entities:
Keywords: RNA metabolism; amyotrophic lateral sclerosis; frontal temporal dementia; mRNA translation; neurodegeneration; neurodevelopment; nonsense-mediated mRNA decay
Mesh:
Substances:
Year: 2021 PMID: 33783512 PMCID: PMC8339359 DOI: 10.1093/jmcb/mjab022
Source DB: PubMed Journal: J Mol Cell Biol ISSN: 1759-4685 Impact factor: 6.216
Summary of phenotypes observed in NMD factor loss-of-function animal models.
| NMD factor | Functions | Species | Genotype | Phenotype | References |
|---|---|---|---|---|---|
| UPF1/SMG2 | ATP-dependent 5′−3′ RNA helicase; recruits UPF2 and UPF3 near the PTC; phosphorylated by SMG1 and activates NMD |
| Loss-of-function mutants | Viable, mild defects in tail, bursal, and vulval development |
|
|
| Missense and nonsense mutations | Lethality during larval development, rescued by loss of Gadd45 |
| ||
| Zebrafish | Knockdown by morpholinos | Embryonic lethality, brain patterning and midbrain–hindbrain boundary defects, brain necrosis, somitogenesis impairment |
| ||
| Mouse | Global knockout | Embryonic lethality, apoptosis at blastocyst stage |
| ||
| UPF2/SMG3 | Branch-specific NMD factor; recruited to the EJC via UPF3B interactions; bridges UPF1 and the EJC |
| Loss-of-function mutants | Viable, mild defects in tail, bursal, and vulval development |
|
|
| Null mutant | Lethality during larval development, defects in NMJ synaptic transmission |
| ||
|
| Brain-specific knockdown by RNAi | Impaired long-term memory |
| ||
| Zebrafish | Knockdown by morpholinos | Embryonic lethality, developmental defects similar to Upf1 knockdown |
| ||
| Mouse | Global knockout | Embryonic lethality between E3.5 and E7.5 |
| ||
| Mouse | Liver-specific knockout | Perinatal lethality, impaired liver development, activated DNA damage response |
| ||
| Mouse | Forebrain-specific knockout | Impaired hippocampal synaptic plasticity and long-term memory, deficits in social behaviors and behavioral inflexibility, neuroinflammation |
| ||
| UPF3/SMG4 | Branch-specific NMD factor; interacts with the EJC; recruits UPF2; in vertebrates, UPF3A is a partially redundant but less active paralog of UPF3B |
| Loss-of-function mutants | Viable, mild defects in tail, bursal, and vulval development |
|
|
| Null mutant | Viable, fertile, no severe developmental defects |
| ||
| Zebrafish | Knockdown by morpholinos | Upf3a: weak brain patterning defect, viable; Upf3b: no apparent phenotype; double knockdown: mild phenotype similar to Upf1 mutant, few with brain necrosis, 19% lethality at 5 days post-fertilization |
| ||
| Mouse |
| Global knockout: embryonic lethality between E4.5 and E8.5; male germ cell-specific knockout: spermatogenesis defects; olfactory epithelium-specific knockout: reduced NMD target abundance |
| ||
| Mouse |
| Impaired fear-conditioned learning and prepulse inhibition, dendritic spine maturation deficits |
| ||
| SMG1 | PI3K-related kinase; phosphorylates UPF1 at S/TQ motifs and activates NMD |
| Loss-of-function mutants | Viable, mild defects in tail, bursal, and vulval development |
|
|
| Null mutant | Viable, fertile, impaired synaptic transmission, impaired synaptic vesicle recycling |
| ||
| Zebrafish | Knockdown by morpholinos | No phenotype observed in embryos |
| ||
| Mouse | Global knockout | Embryonic lethality, developmental arrest at E8.5 |
| ||
| SMG5 | NMD effector; recruited near the PTC by phosphorylated UPF1; promotes deadenylation and RNA decay; promotes dephosphorylation of UPF1 by recruiting PP2A |
| Loss-of-function mutants | Viable, mild defects in tail, bursal, and vulval development |
|
|
| Loss-of-function mutants | Developmental delay in larval stage and lethality during pupariation, synthetic lethality between Smg5 hypomorph and Smg1 null |
| ||
| Zebrafish | Knockdown by morpholinos | Embryonic lethality, developmental defects similar to Upf1 knockdown |
| ||
| SMG6 | Endonuclease; recruited by phosphorylated UPF1; cleaves mRNAs near the PTC |
| Loss-of-function mutants | Viable, mild defects in tail, bursal, and vulval development |
|
|
| Loss-of-function mutants | Partially functional NMD, moderate reduction in viability, growth disadvantage of mutant cells when competing with wild-type cells, impaired NMJ synaptic transmission |
| ||
| Zebrafish | Knockdown by morpholinos | Embryonic lethality, developmental defects similar to Upf1 knockdown |
| ||
| Mouse | Global knockout | Embryonic lethality at the blastocyst stage |
| ||
| SMG7 | NMD effector; promotes deadenylation and RNA decay; promotes dephosphorylation of UPF1 |
| Loss-of-function mutants | Viable, temperature-sensitive defect in NMD |
|
| Zebrafish | Knockdown by morpholinos | Elongated hindbrain, altered midbrain to hindbrain boundary, stacked somites, bent tails |
|
Figure 1A hypothetical model of selective neuronal vulnerability to NMD perturbations. During neuronal differentiation, NMD activity is suppressed by miRNAs to a minimal level required for viability. Additional insults to NMD, either by genetic mutations in NMD factor genes (early onset, e.g. UPF3B) or by the accumulation of NMD-inactivating molecules (late onset, e.g. R-DPR), would further reduce the activity below the required threshold, leading to pathological outcomes.
Figure 2NMD inhibition by C9orf72 R-DPRs drives a positive feedback loop. In normal neurons, cytoplasmic intron-retaining mRNAs are efficiently detected and degraded by NMD. In neurons carrying the C9orf72 hexanucleotide repeat expansion, however, RAN translation of the repeat intron-retaining C9orf72 mRNAs produces R-DPRs, which inhibits global translation and NMD. This global NMD deficit allows more aberrant RNAs, presumably including the repeat-containing C9orf72 mRNA, to accumulate in cytoplasm. Excessive aberrant RNAs may also in turn overload the already reduced NMD capacity in C9ALS/FTD neurons.